An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary Hypertension

New England Journal of Medicine

Volumn 327, Issue 2, 1992, Pages 70-75

  Christman, Brian W ^a   Mcpherson, Charles D ^a   Newman, John H ^a   King, Gayle A ^a   Bernard, Gordon R ^a   Groves, Bertron M ^b   Loyd, James E ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN; THROMBOXANE A2;

ADULT; ARTICLE; BLOOD VESSEL INJURY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART CATHETERIZATION; HUMAN; KIDNEY CLEARANCE; MALE; METABOLITE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RADIOIMMUNOASSAY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; URINARY EXCRETION; VASOCONSTRICTION;

EID: 0026628265     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199207093270202     Document Type: Article

References (33)

1. Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970; 42: 1163–84.
2. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart. Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 60: 1198–206.
3. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease: a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958; 18: 533–47.
4. Voelkel NF, Weir EK. Etiologic mechanisms in primary pulmonary hypertension. In: Weir EK, Reeves JT, eds. Pulmonary vascular physiology and pathophysiology. Vol. 38 of Lung biology in health and disease. New York: Marcel Dekker, 1989:513–39.
5. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580–7.
6. Cohen M, Edwards WD, Fuster V. Regression in thromboembolic type of primary pulmonary hypertension during 2 1/2 years of antithrombotic therapy. J Am Coll Cardiol 1986; 7: 172–5.
7. Reeves JT, Groves BM, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis 1986; 134: 342–6.
8. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989; 140: 1623–30.
9. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990; 112: 485–91.
10. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987; 76: 135–41.
11. Barst RJ, Stalcup SA, Steeg CN, et al. Relation of arachidonate metabolites to abnormal control of the pulmonary circulation in a child. Am Rev Respir Dis 1985; 131: 171–7.
12. Rich S, Hart K, Kieras K, Brundage BH. Thromboxane synthetase inhibition in primary pulmonary hypertension. Chest 1987; 91: 356–60.
13. Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 1986; 77: 590–4.
14. Catella F, FitzGerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res 1987; 47: 647–56.
15. Ciabattoni G, Boss AH, Daffonchio L, et al. Radioimmunoassay measurement of 2,3-dinor metabolites of prostacyclin and thromboxane in human urine. Adv Prostaglandin Thromboxane Leukot Res 1987; 17: 598–602.
16. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983–9.
17. Christman BW, Blair IA. Analysis of platelet activating factor in human saliva by gas chromatography/mass spectrometry. Biomed Environ Mass Spectrom 1989; 18: 258–64.
18. Siegel S, Castellan NJ Jr. Nonparametric statistics for the behavioral sciences. 2nd ed. New York: McGraw-Hill, 1988.
19. Young RH, Mark GJ. Pulmonary vascular changes in scleroderma. Am J Med 1978; 64: 998–1004.
20. Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983; 75: 65–74.
21. Kahaleh MB, Osborn I, Leroy EC. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 1982; 96: 610–3.
22. Nair SS, Askari AD, Popelka CG, Kleinerman JF. Pulmonary hypertension and systemic lupus erythematosus. Arch Intern Med 1980; 140: 109–11.
23. Turner-Stokes L, Turner-Warwick M. Intrathoracic manifestations of SLE. Clin Rheum Dis 1982; 8: 229–42.
24. Rich S, Kieras K, Hart K, Groves BM, Stobo JD, Brundage BH. Antinuclear antibodies in primary pulmonary hypertension. J Am Coll Cardiol 1986; 8: 1307–11.
25. Groves BM, Brundage BH, Elliott CG, et al. Pulmonary hypertension associated with hepatic cirrhosis. In: Fishman AP, ed. The pulmonary circulation: normal and abnormal: mechanisms, management, and the national registry. Philadelphia: University of Pennsylvania Press, 1990:359–69.
26. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykoski RK, Edwards JE. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987; 10: 1233–8.
27. Henriksson P, Wennmalm A, Edhag O, Vesterqvist O, Green K. In vivo production of prostacyclin and thromboxane in patients with acute myocardial infarction. Br Heart J 1986; 55: 543–8.
28. Vesterqvist O, Green K, Johnsson H. Thromboxane and prostacyclin formation in patients with deep vein thrombosis. Thromb Res 1987; 45: 393–402.
29. Badesch DB, Orton EC, Zapp LM, et al. Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. Am J Respir Cell Mol Biol 1989; 1: 489–98.
30. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464–9.
31. Herve P, Drouet L, Dosquet C, et al. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. Am J Med 1990; 89: 117–20.
32. Hart CM, Block ER. Lung serotonin metabolism. Clin Chest Med 1989; 10: 59–70.
33. Dinh-Xuan AT, Higenbottam TW, Clelland CA, et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991; 324: 1539–47.